Bris­tol My­ers’ Op­du­alag stum­bles in late-stage re­sect­ed melanoma tri­al

Bris­tol My­ers Squibb’s LAG-3/PD-1 tar­get­ing im­munother­a­py Op­du­alag failed to boost sur­vival in pa­tients with ad­vanced skin can­cer in a Phase 3 study, mark­ing the lat­est …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER